Hospital

Neutralizing monoclonal antibody therapies found to improve outcomes for unvaccinated and nonhospital patients at high risk of poor outcome for SARS-CoV-2.

Study shows eplontersen maintains a consistent and sustained treatment effect and reinforces its potential treating hereditary transthyretin-mediated amyloid polyneuropathy, which can lead to heart failure.

Immature data suggest enzalutamide combination improves overall survival in patients with high-risk biochemical recurrence.

Health-system pharmacies should fight the well-orchestrated attempt to dismantle 340B drug pricing.

The system is considered effective at identifying residual breast cancer following surgical resection.

An increase in the use of GLP-1 agonists for weight loss is affecting patients with diabetes who rely on these medications.

The treatment showed significant improvement in patients in patients who require frequent blood transfusions and are at risk of infection.

Naveen Mansukhani, BPharm, discussed skyrocketing prices for specialty drugs and what is driving those increases.

Balancing clinicians’ priorities with the needs of patients and their families is crucial to ensure access and adherence to medications.

Cephalosporin treatment is a risk factor of Clostridioides difficile infection.

Screening tools are becoming widely used to help clinicians address the needs of patients with diabetes to improve health outcomes.

Relative risk of cancer-related death differed according to age of diagnosis.

Pharmacists play key roles in navigating prior authorizations and other limits on utilization, as well as educating and listening to patients and caregivers.

Nearly 18-times more patients on trizepatide 15 mg achieved a body weight reduction of 15% or more compared to placebo.

Key topics in May include mental illness for pharmacists, pharmacy technicians, and PharmD candidates.

The BCG vaccine was more likely to cause symptomatic or severe COVID-19 in patients that had a preexisting condition, such as heart disease, by 6 months.

Given the increasing value of patient satisfaction in determining the quality of care in the hospital reimbursement model, research is flourishing with a focus on identifying the factors that could positively influence patient satisfaction outcomes.

The flexible 1- and 2-month dosing intervals of risperidone could help address adherence challenges common with schizophrenia treatments.

Study shows intramuscular injection may improve treatment success by increasing the speed of drug absorption.

Investigators suggest that a checklist completed by physicians and family members of individuals with severe acute brain injury may improve management needs.

Analysis shows that the ratio of neutralizing antibody geometric mean titers in adolescents compared with young adults was 1.5 after vaccination with NVX-CoV2373.

The willingness of biology labs to evolve has been essential to the incredible rise of biologic drugs.

The formulation in 960 mg and 720 mg prefilled syringes delivers sustained plasma concentrations comparable to those demonstrated in studies with Abilify Maintena.

Proposed rules would permit a telehealth provider to prescribe only up to a 30-day supply of a Schedule III-V non-narcotic controlled substance or buprenorphine through telehealth without the patient first being evaluated in person by a provider.

Nearly 84% of hospitals are working to prevent and mitigate burnout, with increased support and programs for individual wellness and resilience practices.

Risk of incident diabetes was markedly higher among males and in those with more severe COVID-19.

Prevnar 20 is a next-generation pneumococcal conjugate vaccine that includes capsular polysaccharide conjugates for the 13 serotypes already included in Prevnar 13.

The APPOINT-PNH study showed that twice-daily LNP023 (Iptacopan) helped patients with paroxysmal nocturnal hemoglobinuria control intravascular hemolysis.

Through 8 weeks after treatment, C. difficile recurrence in SER-109-treated participants was lower compared to placebo-treated participants.

Less than 20% of physicians were open to starting a patient with nonvalvular atrial fibrillation on an anticoagulant after conducting a clinical review of the patient’s care.